Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, de Reijke TM, Fossà SD. Collette L, et al. Among authors: van andel g. J Clin Oncol. 2004 Oct 1;22(19):3877-85. doi: 10.1200/JCO.2004.07.089. J Clin Oncol. 2004. PMID: 15459209
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W. Oddens JR, et al. Among authors: van de beek c, van andel g. Eur Urol. 2014 Oct;66(4):694-701. doi: 10.1016/j.eururo.2014.05.033. Epub 2014 Jun 16. Eur Urol. 2014. PMID: 24948466 Clinical Trial.
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. Cambier S, et al. Among authors: van andel g. Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23. Eur Urol. 2016. PMID: 26210894 Clinical Trial.
Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911.
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Alfred Witjes J, Oosterlinck W. Oddens JR, et al. Among authors: van de beek c, van andel g. BJU Int. 2016 Sep;118(3):423-8. doi: 10.1111/bju.13474. Epub 2016 Apr 2. BJU Int. 2016. PMID: 26945890 Clinical Trial.
Incidental carcinoma of the prostate.
van Andel G, Vleeming R, Kurth K, de Reijke TM. van Andel G, et al. Semin Surg Oncol. 1995 Jan-Feb;11(1):36-45. doi: 10.1002/ssu.2980110106. Semin Surg Oncol. 1995. PMID: 7538693 Review.
61 results